Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Navamedic M&A Activity 2016

Jul 5, 2016

3668_iss_2016-07-05_5d79fd21-ba4e-421b-9139-bed3ac515a3a.html

M&A Activity

Open in viewer

Opens in your device viewer

Navamedic ASA: Ends partnership with Aspen Pharma in 2017

Navamedic ASA: Ends partnership with Aspen Pharma in 2017

Oslo, 5 July 2016 - Navamedic ASA (OSE: NAVA), the Norwegian medtech and

pharmaceutical products company, today announced that its partnership agreement

with pharmaceutical manufacturer Aspen Pharmacare Holdings ("Aspen") for

distribution of products in the Nordics, will not be renewed from mid-May 2017.

The partnership termination is in line with Navamedic's 13 June 2016

announcement on the strategic partnership with TopRidge Pharma Limited.

"As announced in our stock exchange notification on the strategic partnership

with TopRidge Pharma, we had low expectations on a renewal of our partnership

with Aspen for distribution of their products in the Nordics. Aspen will build

their own organization and market and sell the products in their own name moving

forward, while Navamedic will focus on developing its promising strategic

partnership and long term distribution agreement with TopRidge Pharma, as well

as the development and commercialisation of Sippi. We also continue to evaluate

further expansion of our product and partnership portfolio," says Tom Rönnlund,

Chief Executive Officer of Navamedic.

Navamedic has distributed Aspen products in the Nordic and Benelux markets since

2010. The current contract expires mid-May 2017.

"As the Aspen partnership agreement comes to an end in May next year, we are

looking ahead and leveraging our business model for long term operational and

financial growth focusing on new partnerships, new products and new markets,"

says Rönnlund.

For further information, please contact:

Tom Rönnlund, CEO, Navamedic. Telephone +46 727 320 321.

About Navamedic

Navamedic ASA is a Norwegian medtech and pharmaceutical products company,

delivering products to patients, hospitals and pharmacies in the Nordic and

Benelux markets. The Group's Medtech business has developed, and is currently

introducing, the next generation of digital urine meter, Sippi®. Navamedic's

Pharma and Healthcare business is a distributor of products supplied by a number

of pharmaceutical manufacturers. Navamedic is listed on the Oslo Stock Exchange

(ticker: NAVA).

[HUG#2025650]